Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ENROLLING BY INVITATION
NCT06257420

Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions

Sponsor: Simmaron Research Inc.

View on ClinicalTrials.gov

Summary

The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy. The main questions this study aims to answer are: * Does rapamycin reduce the overall symptom burden in this patient population and does it improve the quality of life? * Does rapamycin change mTOR driven autophagy deficits observed in a subset of patients? Participants will be asked to complete a series of questionnaires and quality of life instruments before starting rapamycin therapy prescribed by their physician and throughout their course of treatment. Study blood samples will be collected before starting therapy and throughout the course of treatment to assess serological markers of autophagy function.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

OBSERVATIONAL

Enrollment

150

Start Date

2023-12-11

Completion Date

2026-06-11

Last Updated

2024-11-05

Healthy Volunteers

No

Interventions

DRUG

Rapamycin

Once weekly oral rapamycin

Locations (5)

Center For Complex Diseases

Palo Alto, California, United States

The Mayo Clinic

Rochester, Minnesota, United States

Sierra Internal Medicine

Incline Village, Nevada, United States

Bateman Horne Center

Salt Lake City, Utah, United States

Center For Complex Diseases

Seattle, Washington, United States